In which industries is Pfizer primarily active?

Pfizer Inc is primarily active in the pharmaceutical industry.

Who are the main competitors of Pfizer in the market?

The main competitors of Pfizer Inc in the market include pharmaceutical companies such as Johnson & Johnson, Novartis AG, Merck & Co., Inc., and GlaxoSmithKline plc.

What is the history and background of the company Pfizer?

Pfizer Inc. is a renowned pharmaceutical giant with a rich history and influential background. Established in 1849, Pfizer has evolved into one of the largest global pharmaceutical companies. Headquartered in New York City, Pfizer has played a pivotal role in the healthcare industry's advancement. The company is committed to developing innovative medicines and vaccines that improve and save lives worldwide. With its vast expertise, extensive research and development efforts, and strategic collaborations, Pfizer has introduced groundbreaking treatments for various diseases. As a leader in the pharmaceutical sector, Pfizer continues to prioritize delivering transformative healthcare solutions to address the evolving needs of patients and healthcare professionals.

What significant milestones has the company Pfizer achieved?

Pfizer Inc has achieved significant milestones throughout its history. Founded in 1849, the company has become one of the world's leading pharmaceutical corporations. Notably, Pfizer developed and marketed groundbreaking drugs that have revolutionized medical treatments. In 1998, the company gained immense recognition with the introduction of Viagra, a medication for erectile dysfunction. Pfizer's research and innovation also led to the development of Lipitor, a cholesterol-lowering drug that became the best-selling prescription medicine worldwide. Furthermore, Pfizer remains dedicated to advancing healthcare by continuously expanding its product portfolio and pursuing collaborations to address unmet medical needs. With its rich history and commitment to innovation, Pfizer Inc continues to make significant contributions to the healthcare industry.

In which countries and regions is Pfizer primarily present?

Pfizer Inc is primarily present in various countries and regions across the globe. The company has a widespread presence with operations in multiple key markets. Pfizer's global presence includes major countries such as the United States, United Kingdom, Germany, Japan, China, India, Brazil, and many more. With a diverse international footprint, Pfizer Inc continues to serve patients and healthcare professionals worldwide by delivering innovative healthcare solutions and medications.

What values and corporate philosophy does Pfizer represent?

Pfizer Inc, a renowned pharmaceutical company, represents values of integrity, excellence, and patient-centricity. With a strong corporate philosophy, Pfizer aims to improve the health and well-being of individuals worldwide through innovative medicines and therapies. Committed to scientific advancement, Pfizer provides quality healthcare solutions while upholding ethical practices. Through extensive research and development, they strive to discover and deliver life-saving and life-enhancing treatments. As a global leader in the healthcare industry, Pfizer's dedication to patient care, scientific ingenuity, and ethical principles are fundamental to their corporate philosophy and drive their mission to revolutionize healthcare for a better tomorrow.

What is the business model of Pfizer?

Pfizer Inc is a multinational pharmaceutical company headquartered in New York City. The company operates in the research, development, production, and distribution of drugs. Pfizer is one of the largest pharmaceutical companies in the world. In this article, we will describe the business model of Pfizer Inc. Divisions Pfizer has divided its business operations into three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. Biopharmaceuticals The Biopharmaceuticals division focuses on the research and development of drugs. The goal is to develop new drugs and therapies that meet the needs of patients. Research and development are focused on various areas such as oncology, cardiovascular, immunological, and neuroscience disorders. Pfizer has a strong pipeline with numerous drugs in late-stage clinical development. An example is the drug Tofacitinib, which is used to treat rheumatoid arthritis. In 2020, Pfizer generated revenue of $51.8 billion in this division. Beyond the Baby Cure The Beyond the Baby Cure division refers to products that are not drug-based. This includes products like vitamin-rich dietary supplements, pain relievers, condoms, and personal care products. Pfizer acquired Wyeth in 2006, a company active in this segment. This allowed Pfizer to expand its product portfolio. In 2020, Pfizer generated revenue of $2.5 billion in this segment. Contract Manufacturing Pfizer's Contract Manufacturing division refers to the production of drugs for other companies. The company offers services for the entire value chain, from drug manufacturing to logistics. In 2020, Pfizer generated revenue of $2.2 billion in this division. Products Pfizer offers a wide range of products covering various areas. Here are some of Pfizer's key products: - Viagra, a medication for the treatment of erectile dysfunction - Lyrica, a medication for the treatment of neuropathic pain - Prevnar, a vaccine for the prevention of pneumococcal infections - Xeljanz, a medication for the treatment of rheumatoid arthritis - Lipitor, a medication for lowering cholesterol levels Conclusion Pfizer is a leading pharmaceutical company with a broad portfolio of products and services. The company specializes in three main divisions: Biopharmaceuticals, Beyond the Baby Cure, and Contract Manufacturing. With a strong commitment to research and development and an impressive pipeline, Pfizer has a strong position in the industry.

What is the revenue of Pfizer 2026?

The expected revenue of Pfizer is 61.65 B USD. This figure is based on current financial data and reflects the company's business performance.

How high is the profit of Pfizer 2026?

The expected profit of Pfizer is 17.16 B USD. The net profit reflects the company's profitability after deducting all expenses.

What is the P/E ratio of Pfizer 2026?

The price-to-earnings ratio (P/E) of Pfizer is currently 8.76. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pfizer stock.

What is the P/S ratio of Pfizer 2026?

The price-to-sales ratio (P/S) of Pfizer is currently 2.44. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pfizer stock.

What is the Eulerpool Quality Score of Pfizer?

The Eulerpool Quality Score for Pfizer is 2/10.

What is the Pfizer ISIN?

The ISIN of Pfizer is US7170811035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

What is the Pfizer WKN?

The WKN of Pfizer is 852009. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

What is the Pfizer ticker?

The ticker of Pfizer is PFE. The ticker symbol is used to trade Pfizer shares on the stock exchange.

How much dividend does Pfizer pay?

Over the past 12 months, Pfizer paid a dividend of 1.72 USD . This corresponds to a dividend yield of about 6.53 %. For the coming 12 months, Pfizer is expected to pay a dividend of 1.24 USD.

What is the dividend yield of Pfizer?

The current dividend yield of Pfizer is 6.53 %.

When does Pfizer pay dividends?

Pfizer pays a dividend, distributed in the months of , , , .

How secure is the dividend of Pfizer?

Pfizer paid dividends every year for the past 36 years.

What is the dividend of Pfizer?

For the upcoming 12 months, dividends amounting to 1.24 USD are expected. This corresponds to a dividend yield of 4.84 %.

In which sector is Pfizer located?

Pfizer is assigned to the 'Health' sector.

When did I have to buy Pfizer shares to receive the previous dividend?

To receive the latest dividend of Pfizer from amounting to 0.43 USD, you needed to have the stock in your portfolio before the ex-date on .

When did Pfizer pay the last dividend?

The last dividend was paid out on .

What was the dividend of Pfizer in the year 2025?

In the year 2025, Pfizer distributed 1.69 USD as dividends.

In which currency does Pfizer pay out the dividend?

The dividends of Pfizer are distributed in USD.

Start Free Trial

Pfizer (PFE) Stock Price

Currency:

Pfizer Price

🇺🇸NASDAQ·CLOSED

26.32USD

Market closed

Today +/-

Today %

Pfizer (PFE) Stock | ISIN US7170811035 | WKN 852009. The current Pfizer stock price is 26.32 USD (2026). Revenue is 61.65 B USD. Net income is 17.16 B USD. The P/E ratio is 8.76. Market capitalization is 150.37 B USD. Pfizer operates in the Health sector.

Pfizer stock price

Ex-Dividend

Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Pfizer over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Pfizer stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Pfizer's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Pfizer Stock Price History

Date	Pfizer Price

Access this data via the Eulerpool API

Docs Get Free API Key

Pfizer Revenue, EBIT, Net Income

3 Years
5 Years
10 Years
25 Years
Max

Revenue

EBIT

Net Income

Details

Pfizer Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 12, 2026, 4:28 AM

REVENUE (B USD)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (B USD)

NET INCOME (B USD)

NET INCOME GROWTH (%)

DIVIDEND (USD)DIV. (USD)

DIVIDEND GROWTH (%)DIV. GROWTH (%)

SHARES (B)

DOCUMENTS

2024	2025	2026e	2027e	2028e	2029e	2030e	2031e
63.63	62.58	61.65	59.32	54.89	53.14	52.83	54.2
6.84	-1.65	-1.48	-3.78	-7.48	-3.19	-0.58	2.61
74.33	75.81	76.94	79.97	86.43	89.28	89.8	87.52
47.3	47.44	47.44	47.44	47.44	47.44	47.44	47.44
8.03	7.77	17.16	16.46	15.58	12.39	12.68	13.6
279	-3.24	120.78	-4.04	-5.34	-20.53	2.4	7.24
1.68	1.72	0.43	1.24	1.19	-	-	-
-18.05	2.38	-75	188.37	-4.03	–	–	–
5.7	5.71	5.71	5.71	5.71	5.71	5.71	5.71
–	–	–	–	–	–	–	–

Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Pfizer generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Pfizer retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Pfizer's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Pfizer has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Pfizer's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Pfizer stock margins

The Pfizer margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Pfizer. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Pfizer.

3 Years
5 Years
10 Years
25 Years
Max

Gross margin

EBIT margin

Profit margin

Details

Pfizer Stock Revenue, EBIT, Earnings per Share

The Pfizer earnings per share therefore indicates how much revenue Pfizer has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 Years
5 Years
10 Years
25 Years
Max

Revenue per Share

EBIT per share

Earnings per Share

Details

Pfizer business model & stock analysis

Pfizer Inc, one of the world's largest and most well-known pharmaceutical companies, has made significant advancements in the medical industry throughout its approximately 170-year history. The company is headquartered in New York City and has offices in over 150 countries. Pfizer was founded in 1849 by two cousins, Charles Pfizer and Charles Erhart, who opened their first factory in Brooklyn to produce pure crystalline chinasalt. They later expanded their business and began synthesizing chemical compounds, leading them to enter the pharmaceutical industry. In the following years, Pfizer made some significant discoveries, including the synthesis of antibiotics such as penicillin and terramycin. In the 1990s, the company expanded its portfolio and became a leading provider of prescription drugs, immunological medications, and animal health products. Today, the company focuses on three core areas: innovative health products, patented medications, and generic products. Pfizer invests millions of dollars in research and development of new and innovative treatment options, including cancer drugs, therapies for neurological disorders, cardiovascular diseases, and immunology products. Another important aspect of Pfizer's business model is its partnerships with other companies and organizations. The company works closely with universities, research institutions, governments, and other companies to form partnerships that allow for collaborative development of new products. Some of Pfizer's most well-known products include Viagra, Lipitor, Celebrex, Zoloft, and Lyrica. Viagra is used to treat erectile dysfunction in men. Lipitor is a cholesterol-lowering medication that reduces the risk of cardiovascular diseases. Celebrex is an anti-inflammatory medication used to treat pain and inflammation. Zoloft is an antidepressant used to treat various mental disorders. Lyrica is a prescription medication used to treat pain and seizures. In recent years, Pfizer has also taken a leading role in the development of vaccines against COVID-19, collaborating with the German company BioNTech to develop a promising vaccine candidate. The vaccine provides protection against the virus, particularly against severe illness. Over the years, the company has faced concerns regarding the use of medications, such as the scandal surrounding the pain reliever Vioxx, which was withdrawn in 2004 after being associated with an increased risk of cardiovascular diseases. Pfizer has since strengthened its research and development standards and partnerships to ensure the safety and efficacy of its products. In summary, Pfizer is a global player in the pharmaceutical industry. The company heavily invests in research and development of new products to provide innovative treatment options, secures patents, and simultaneously keeps its portfolio up-to-date with generic products to remain competitive in the industry. The company will continue to contribute to improving healthcare worldwide by developing lifesaving medications and vaccines that enable people to lead better lives.

Pfizer SWOT Analysis

Strengths

Pfizer Inc. possesses several strengths that contribute to its success in the pharmaceutical industry. One of its key strengths is its extensive portfolio of innovative drugs and treatments. The company invests heavily in research and development, allowing it to continuously develop and introduce new products to the market. Pfizer's strong brand reputation and global presence also contribute to its competitive advantage.

Another major strength is Pfizer's robust financial position. The company has a solid revenue stream, driven by the high demand for its products, and maintains a strong profitability margin. This financial stability enables Pfizer to invest in strategic acquisitions and partnerships, further strengthening its position in the industry.

Weaknesses

Despite its strengths, Pfizer Inc. also faces certain weaknesses that need to be addressed. One weakness is its heavy reliance on a few key products for a significant portion of its revenue. This exposes the company to risks associated with patent expirations and competition from generic drug manufacturers. Pfizer needs to focus on diversifying its product portfolio to reduce this dependency.

Another weakness is the potential negative impact of regulatory changes and legal issues on Pfizer's operations. The pharmaceutical industry is subject to strict regulations, and any change or legal challenge can disrupt Pfizer's business activities and profitability. Close monitoring of regulatory developments and proactive compliance strategies are essential to mitigate these risks.

Opportunities

Pfizer Inc. has several opportunities to capitalize on in the constantly evolving pharmaceutical market. One significant opportunity lies in the growing demand for personalized medicine and targeted therapies. Pfizer can leverage its expertise and research capabilities to develop innovative treatments that cater to specific patient populations, creating a competitive edge in the market.

Furthermore, the increasing focus on healthcare and medical advancements presents an opportunity for Pfizer to expand into emerging markets with high growth potential. By targeting underserved regions, the company can tap into new customer segments and drive revenue growth. Strategic collaborations with local healthcare providers and governments can further enhance Pfizer's market penetration in these regions.

Threats

Like any other company in the pharmaceutical industry, Pfizer Inc. faces several threats that could impact its business. One major threat is the intense competition within the market. The industry is highly competitive, with numerous pharmaceutical companies striving to develop breakthrough drugs and gain market share. Pfizer needs to continuously innovate and stay ahead to maintain its competitive position.

Additionally, the potential risk of counterfeit drugs poses a threat to Pfizer's reputation and revenue. Counterfeit drugs can harm patients and erode trust in the company's products. Pfizer should strengthen its supply chain security and invest in advanced technologies to detect and combat counterfeit drugs effectively.

Moreover, changes in healthcare policies and pricing regulations can significantly impact Pfizer's profitability. Government policies aimed at cost containment or price controls can restrict the company's ability to set prices for its products, thereby affecting its financial performance. Continuous monitoring of these policies and proactive engagement with policymakers is crucial to minimize potential risks.

Pfizer Segments

Pfizer Revenue by Segment (1/14)

Padcev

Details

Pfizer Revenue by Segment (2/14)

3 Years
5 Years
Max

Alliance Biopharmaceuticals

Prevenar 13/Prevnar 13

Total Sterile Injectable Pharmaceuticals

Ibrance

All Other Internal Medicine

Enbrel

Other Hospital Products

Total Biosimilars

Vyndaqel/Vyndamax

Other Anti-infectives

Paxlovid

Xtandi Alliance Revenues

Chantix Champix

Sutent

Inlyta

Premarin Family

Abrysvo

Celebrex

Sulperazon

Inflectra/Remsima

Bosulif

BeneFIX

Xalkori

Other Oncology Products

ReFacto AF Xyntha

Genotropin

Lorbrena

Zavicefta

Ruxience

Medrol

Retacrit

Zirabev

IVIg Products

Vfend

BMP2

Zithromax Zmax

Fragmin

Pristiq

Aromasin

All Other Rare Disease Products

Zyvox

Somavert

Other Vaccines Products

Tygacil

Toviaz

Precedex

Besponsa

Nimenrix

FSME/IMMUN-TicoVac

Braftovi

Trazimera

Bavencio Alliance Revenues

Mektovi

Trumenba

All Other Inflammation and Immunology Products

Details

Date

Alliance Biopharmaceuticals

Prevenar 13/Prevnar 13

Total Sterile Injectable Pharmaceuticals

Ibrance

All Other Internal Medicine

Enbrel

Other Hospital Products

Total Biosimilars

Vyndaqel/Vyndamax

Pfizer CentreOne

Other Anti-infectives

Paxlovid

Xtandi Alliance Revenues

Chantix Champix

Sutent

Inlyta

Premarin Family

Abrysvo

Celebrex

Sulperazon

Inflectra/Remsima

Bosulif

BeneFIX

Xalkori

Other Oncology Products

ReFacto AF Xyntha

Genotropin

Lorbrena

Zavicefta

Ruxience

Medrol

Retacrit

Zirabev

IVIg Products

Vfend

BMP2

Zithromax Zmax

Fragmin

Pristiq

Aromasin

All Other Rare Disease Products

Zyvox

Somavert

Panzyga

Other Vaccines Products

Tygacil

Toviaz

Precedex

Besponsa

Nimenrix

FSME/IMMUN-TicoVac

Braftovi

Trazimera

Bavencio Alliance Revenues

Mektovi

Trumenba

All Other Inflammation and Immunology Products

Jan 1, 2011

0 USD

Jan 1, 2014

0 USD

Jan 1, 2015

0 USD

Jan 1, 2016

0 USD

Jan 1, 2017

0 USD

Jan 1, 2018

0 USD

Jan 1, 2019

0 USD

719 M USD

0 USD

Jan 1, 2021

7.65 B USD

5.27 B USD

5.75 B USD

5.44 B USD

1.71 B USD

1.19 B USD

2.41 B USD

2.34 B USD

2.02 B USD

0 USD

1.45 B USD

76 M USD

1.19 B USD

398 M USD

673 M USD

1 B USD

563 M USD

0 USD

683 M USD

657 M USD

540 M USD

438 M USD

493 M USD

238 M USD

304 M USD

389 M USD

266 M USD

413 M USD

491 M USD

432 M USD

444 M USD

430 M USD

267 M USD

266 M USD

278 M USD

305 M USD

187 M USD

211 M USD

115 M USD

173 M USD

277 M USD

0 USD

74 M USD

200 M USD

238 M USD

177 M USD

192 M USD

193 M USD

185 M USD

187 M USD

197 M USD

178 M USD

155 M USD

118 M USD

134 M USD

Jan 1, 2023

0 USD

890 M USD

0 USD

174 M USD

0 USD

Pfizer Revenue by Segment (3/14)

3 Years
5 Years
Max

Alliance Biopharmaceuticals

Prevenar 13/Prevnar 13

Total Sterile Injectable Pharmaceuticals

Ibrance

Lyrica

All Other Internal Medicine

Enbrel

Other Hospital Products

Total Biosimilars

Vyndaqel/Vyndamax

Lipitor

Pfizer CentreOne

All Other Upjohn Products

Other Anti-infectives

Paxlovid

Xtandi Alliance Revenues

Chantix Champix

Sutent

Inlyta

Premarin Family

Norvasc

Sulperazon

Inflectra/Remsima

Viagra

BeneFIX

Xalkori

Other Oncology Products

ReFacto AF Xyntha

Genotropin

Medrol

Retacrit

Vfend

BMP2

Zithromax Zmax

Effexor

Xalatan Xalacom

Fragmin

All Other Rare Disease Products

Zoloft

Zyvox

Somavert

Panzyga

Other Vaccines Products

Tygacil

Toviaz

Revatio

Nimenrix

FSME/IMMUN-TicoVac

Braftovi

Zosyn / Tazocin

Xanax

Diflucan

Mektovi

Trumenba

All Other Inflammation and Immunology Products

HIS Products

Details

Date

Alliance Biopharmaceuticals

Prevenar 13/Prevnar 13

Total Sterile Injectable Pharmaceuticals

Ibrance

Lyrica

All Other Internal Medicine

Enbrel

Other Hospital Products

Total Biosimilars

Vyndaqel/Vyndamax

Lipitor

Pfizer CentreOne

All Other Upjohn Products

Other Anti-infectives

Paxlovid

Xtandi Alliance Revenues

Chantix Champix

Sutent

Inlyta

Premarin Family

Norvasc

Sulperazon

Inflectra/Remsima

Viagra

BeneFIX

Xalkori

Other Oncology Products

ReFacto AF Xyntha

Genotropin

Medrol

Retacrit

Vfend

BMP2

Zithromax Zmax

Effexor

Xalatan Xalacom

Fragmin

All Other Rare Disease Products

Zoloft

Zyvox

Somavert

Panzyga

Other Vaccines Products

Tygacil

Toviaz

Revatio

Nimenrix

FSME/IMMUN-TicoVac

Braftovi

Zosyn / Tazocin

Xanax

Diflucan

Mektovi

Trumenba

All Other Inflammation and Immunology Products

HIS Products

Jan 1, 2011

0 USD

Jan 1, 2014

0 USD

Jan 1, 2015

0 USD

Jan 1, 2016

0 USD

Jan 1, 2017

0 USD

Jan 1, 2018

0 USD

Jan 1, 2019

4.65 B USD

5.85 B USD

5.04 B USD

4.96 B USD

3.32 B USD

2.52 B USD

1.7 B USD

2.44 B USD

911 M USD

473 M USD

1.97 B USD

810 M USD

1.52 B USD

1.11 B USD

0 USD

838 M USD

1.11 B USD

936 M USD

477 M USD

734 M USD

950 M USD

684 M USD

625 M USD

497 M USD

488 M USD

530 M USD

585 M USD

426 M USD

498 M USD

469 M USD

225 M USD

346 M USD

287 M USD

336 M USD

281 M USD

253 M USD

129 M USD

294 M USD

251 M USD

264 M USD

183 M USD

73 M USD

197 M USD

250 M USD

144 M USD

230 M USD

220 M USD

48 M USD

200 M USD

198 M USD

190 M USD

49 M USD

135 M USD

29 M USD

0 USD

Jan 1, 2021

0 USD

Jan 1, 2023

0 USD

1.28 B USD

0 USD

Pfizer Revenue by Segment (4/14)

3 Years
5 Years
Max

Comirnaty Direct Sales and Alliance Revenues

Alliance Biopharmaceuticals

Eliquis Alliance Revenues and Direct Sales

Prevnar Family

Ibrance

Lyrica

Vyndaqel Family

Xeljanz

All other Specialty Care

All other Primary Care

Pfizer CentreOne

Xtandi Alliance Revenues

All other Anti-infectives

Sutent

Inlyta

Premarin Family

Nurtec ODT/Vydura

Enbrel (Outside the U.S. and Canada)

Sulperazon

Bosulif

Viagra

BeneFIX

Xalkori

Ig Portfolio

Genotropin

Lorbrena

Zavicefta

Ruxience

Inflectra

Medrol

Retacrit

Zirabev

All other Oncology

Vfend

Zithromax

BMP2

Oxbryta

Fragmin

Aromasin

Somavert

FSME-IMMUN/TicoVac

Besponsa

Nimenrix

ReFacto AF/Xyntha

Braftovi

Trazimera

Cresemba

Bavencio Alliance Revenues

Bicillin

Trumenba

Cibinqo

Adcetris

Pfizer Ignite

Tukysa

Tivdak

Details

Date

Comirnaty Direct Sales and Alliance Revenues

Alliance Biopharmaceuticals

Eliquis Alliance Revenues and Direct Sales

Prevnar Family

Ibrance

Lyrica

Vyndaqel Family

Xeljanz

All other Specialty Care

All other Primary Care

Pfizer CentreOne

Xtandi Alliance Revenues

All other Anti-infectives

Sutent

Inlyta

Premarin Family

Nurtec ODT/Vydura

Enbrel (Outside the U.S. and Canada)

Sulperazon

Bosulif

Viagra

BeneFIX

Xalkori

Ig Portfolio

Genotropin

Lorbrena

Zavicefta

Ruxience

Inflectra

Medrol

Retacrit

Zirabev

All other Oncology

Vfend

Zithromax

BMP2

Oxbryta

Fragmin

Aromasin

Somavert

FSME-IMMUN/TicoVac

Besponsa

Nimenrix

ReFacto AF/Xyntha

Braftovi

Trazimera

Cresemba

Bavencio Alliance Revenues

Bicillin

Trumenba

Cibinqo

Adcetris

Pfizer Ignite

Tukysa

Tivdak

Jan 1, 2011

0 USD

Jan 1, 2014

0 USD

Jan 1, 2015

0 USD

Jan 1, 2016

0 USD

Jan 1, 2017

0 USD

Jan 1, 2018

0 USD

3.84 B USD

0 USD

4.97 B USD

0 USD

636 M USD

0 USD

Jan 1, 2019

0 USD

Jan 1, 2021

0 USD

Jan 1, 2023

11.22 B USD

0 USD

6.75 B USD

6.44 B USD

4.75 B USD

0 USD

3.32 B USD

1.7 B USD

2.24 B USD

1.78 B USD

1.27 B USD

1.19 B USD

1.09 B USD

180 M USD

1.04 B USD

397 M USD

928 M USD

830 M USD

757 M USD

645 M USD

0 USD

424 M USD

374 M USD

584 M USD

539 M USD

511 M USD

390 M USD

490 M USD

339 M USD

340 M USD

424 M USD

433 M USD

187 M USD

406 M USD

338 M USD

328 M USD

238 M USD

301 M USD

267 M USD

268 M USD

236 M USD

179 M USD

230 M USD

213 M USD

91 M USD

195 M USD

190 M USD

158 M USD

126 M USD

128 M USD

46 M USD

44 M USD

17 M USD

4 M USD

Pfizer Revenue by Segment (5/14)

3 Years
5 Years
Max

Co-promotion

Product

Epi Pen

Details

Pfizer Revenue by Segment (6/14)

3 Years
5 Years
Max

Comirnaty direct sales and alliance revenues

Bosulif

Details

Pfizer Revenue by Segment (7/14)

3 Years
Max

Eliquis

Xeljanz

Details

Pfizer Revenue by Segment (8/14)

3 Years
5 Years
10 Years
Max

Biopharmaceutical

Alliance Biopharmaceuticals

Eliquis

Prevenar Family

Ibrance

Other Legacy Established Products

Lyrica

All Other Sterile Injectable Pharmaceuticals

Consumer Healthcare

All Other Internal Medicine

Xeljanz

Enbrel

Lipitor

Chantix Champix

Sutent

Inlyta

Premarin Family

Norvasc

Celebrex

Sulperazon

Inflectra/Remsima

Bosulif

Viagra

BeneFIX

Xalkori

Xtandi Alliance

Other Oncology Products

ReFacto AF Xyntha

Genotropin

Other Products

Medrol

Vfend

Other Biopharmaceuticals

BMP2

Zithromax Zmax

Effexor

Xalatan Xalacom

Fragmin

Pristiq

Epi Pen

Zosyn Tazocin

All Other Rare Disease Products

Zoloft

EpiPen

Zyvox

Somavert

FSME-IMMUN/TicoVac

Other Vaccines Products

Tygacil

Toviaz

All Other Peri-LOE Products

Revatio

Precedex

Relpax

Inspra

Xanax/Xanax XR

Detrol Detrol LA

Protonix / Pantoprazole

Tazosyn / Zosyn

Cardura

Diflucan

Dalacin / Cleocin

Neurontin

Caduet

Rapamune

Tikosyn

Eucrisa

All Other Inflammation and Immunology Products

Depo-Provera

Unasyn

All Other Biosimilars

Sildenafil Citrate

Details

Date

Biopharmaceutical

Co-promotion

Alliance Biopharmaceuticals

Eliquis

Prevenar Family

Ibrance

Other Legacy Established Products

Lyrica

All Other Sterile Injectable Pharmaceuticals

Consumer Healthcare

All Other Internal Medicine

Xeljanz

Enbrel

Lipitor

Chantix Champix

Sutent

Inlyta

Premarin Family

Norvasc

Celebrex

Sulperazon

Product

Inflectra/Remsima

Bosulif

Viagra

BeneFIX

Xalkori

Xtandi Alliance

Other Oncology Products

ReFacto AF Xyntha

Genotropin

Other Products

Medrol

Vfend

Other Biopharmaceuticals

BMP2

Zithromax Zmax

Effexor

Xalatan Xalacom

Fragmin

Pristiq

Epi Pen

Zosyn Tazocin

All Other Rare Disease Products

Zoloft

EpiPen

Zyvox

Somavert

FSME-IMMUN/TicoVac

Other Vaccines Products

Tygacil

Toviaz

All Other Peri-LOE Products

Revatio

Precedex

Relpax

Inspra

Xanax/Xanax XR

Detrol Detrol LA

Protonix / Pantoprazole

Tazosyn / Zosyn

Cardura

Diflucan

Dalacin / Cleocin

Neurontin

Caduet

Rapamune

Tikosyn

Eucrisa

All Other Inflammation and Immunology Products

Depo-Provera

Unasyn

All Other Biosimilars

Sildenafil Citrate

Jan 1, 2011

3.66 B USD

0 USD

299 M USD

0 USD

Jan 1, 2014

45.71 B USD

0 USD

957 M USD

0 USD

4.46 B USD

0 USD

5.17 B USD

0 USD

3.45 B USD

0 USD

308 M USD

3.85 B USD

2.06 B USD

647 M USD

1.17 B USD

410 M USD

1.08 B USD

1.11 B USD

2.7 B USD

354 M USD

0 USD

1.69 B USD

856 M USD

438 M USD

0 USD

631 M USD

723 M USD

451 M USD

443 M USD

756 M USD

6.18 B USD

228 M USD

314 M USD

344 M USD

495 M USD

364 M USD

737 M USD

0 USD

303 M USD

0 USD

423 M USD

294 M USD

1.35 B USD

229 M USD

0 USD

323 M USD

288 M USD

0 USD

276 M USD

0 USD

382 M USD

233 M USD

253 M USD

201 M USD

198 M USD

0 USD

263 M USD

220 M USD

184 M USD

210 M USD

180 M USD

339 M USD

0 USD

201 M USD

207 M USD

0 USD

Jan 1, 2015

0 USD

1.31 B USD

0 USD

6.25 B USD

723 M USD

4.57 B USD

3.66 B USD

2.56 B USD

3.4 B USD

0 USD

523 M USD

3.33 B USD

1.86 B USD

671 M USD

1.12 B USD

430 M USD

1.02 B USD

991 M USD

830 M USD

339 M USD

0 USD

411 M USD

752 M USD

488 M USD

0 USD

533 M USD

617 M USD

506 M USD

402 M USD

682 M USD

405 M USD

232 M USD

275 M USD

288 M USD

399 M USD

335 M USD

715 M USD

339 M USD

0 USD

374 M USD

0 USD

883 M USD

218 M USD

104 M USD

0 USD

304 M USD

267 M USD

362 M USD

260 M USD

0 USD

352 M USD

0 USD

224 M USD

0 USD

210 M USD

181 M USD

0 USD

196 M USD

0 USD

197 M USD

179 M USD

0 USD

170 M USD

118 M USD

0 USD

Jan 1, 2016

0 USD

1.59 B USD

0 USD

5.72 B USD

2.14 B USD

4.54 B USD

4.97 B USD

4.58 B USD

0 USD

573 M USD

927 M USD

2.91 B USD

1.76 B USD

842 M USD

1.1 B USD

401 M USD

1.02 B USD

962 M USD

733 M USD

396 M USD

0 USD

192 M USD

0 USD

1.18 B USD

712 M USD

561 M USD

140 M USD

231 M USD

554 M USD

579 M USD

0 USD

450 M USD

590 M USD

0 USD

251 M USD

272 M USD

278 M USD

363 M USD

318 M USD

732 M USD

386 M USD

0 USD

122 M USD

304 M USD

0 USD

421 M USD

232 M USD

114 M USD

239 M USD

274 M USD

258 M USD

276 M USD

285 M USD

0 USD

323 M USD

0 USD

222 M USD

0 USD

192 M USD

119 M USD

0 USD

182 M USD

0 USD

170 M USD

153 M USD

0 USD

93 M USD

126 M USD

0 USD

127 M USD

0 USD

Jan 1, 2017

0 USD

2.93 B USD

2.52 B USD

5.6 B USD

3.13 B USD

5.08 B USD

4.51 B USD

3.72 B USD

0 USD

312 M USD

1.35 B USD

2.45 B USD

1.92 B USD

997 M USD

1.08 B USD

339 M USD

977 M USD

926 M USD

775 M USD

471 M USD

0 USD

419 M USD

233 M USD

382 M USD

604 M USD

594 M USD

590 M USD

93 M USD

551 M USD

532 M USD

0 USD

483 M USD

421 M USD

0 USD

261 M USD

270 M USD

297 M USD

335 M USD

306 M USD

303 M USD

290 M USD

0 USD

300 M USD

291 M USD

0 USD

281 M USD

254 M USD

134 M USD

266 M USD

260 M USD

257 M USD

252 M USD

243 M USD

236 M USD

0 USD

225 M USD

0 USD

194 M USD

0 USD

67 M USD

103 M USD

0 USD

112 M USD

56 M USD

Jan 1, 2018

0 USD

Jan 1, 2019

0 USD

Jan 1, 2021

0 USD

Jan 1, 2023

0 USD

Pfizer Revenue by Segment (9/14)

3 Years
5 Years
Max

Eliquis

Xeljanz

Details

Pfizer Revenue by Segment (10/14)

3 Years
5 Years
Max

Co-promotion

Product

Details

Pfizer Revenue by Segment (11/14)

3 Years
5 Years
Max

Eucrisa

Details

Pfizer Revenue by Segment (12/14)

3 Years
Max

Biopharma

Details

Pfizer Revenue by Segment (13/14)

3 Years
5 Years
10 Years
Max

Innovative Health and Essential Health

Operating Segments

Biopharma Segment

Innovative Health Segment

Global Established Pharmaceutical

Essential Health Segment

Global Innovative Pharmaceutical

Global Vaccines, Oncology and Consumer Healthcare

Pfizer CentreOne

Global Innovative and Established Pharmaceutical

Business Innovation Segment

Details

Pfizer Revenue by Segment (14/14)

3 Years
5 Years
Max

Innovative Health and Essential Health

Details

Pfizer Revenue by Region

3 Years
5 Years
10 Years
Max

United States

United States [Member}

Emerging Markets

Developed Europe

Developed Rest of World

Details

Pfizer Eulerpool Fair Value

Pfizer historical P/E ratio, EBIT multiple, and P/S ratio

Pfizer annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Pfizer shares outstanding

The number of shares was Pfizer in 2025 — This indicates how many shares 5.713 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

3 Years
5 Years
10 Years
25 Years
Max

Number of stocks

Details

Pfizer Dividend History

37 years of dividend payments

YearAnnual DividendYoY ChangePayments

20260.43USDYTD—1×

Jan 23, 20260.43USD 0.0%1/1

20251.72USD↑ 2.4%4×

Jan 24, 20250.43USD↑ 2.4%1/4

May 9, 20250.43USD 0.0%2/4

Jul 25, 20250.43USD 0.0%3/4

Nov 7, 20250.43USD 0.0%4/4

20241.68USD↓ 18.0%4×

20232.05USD↑ 28.1%5×

20221.6USD↑ 2.6%4×

20211.56USD↑ 2.6%4×

20201.52USD↑ 5.6%4×

20191.44USD↑ 5.9%4×

20181.36USD↓ 13.9%4×

20171.58USD↑ 5.3%5×

Pfizer dividend history and estimates

In 2025, Pfizer paid a dividend amounting to 1.72 USD. Dividend means that Pfizer distributes a portion of its profits to its owners.

3 Years
5 Years
10 Years
25 Years
Max

Dividend

Dividend (Estimate)

Details

Pfizer dividend payout ratio

In 2025, Pfizer had a payout ratio of 41.74%. The payout ratio indicates the percentage of the company's profits that Pfizer distributes as dividends.

3 Years
5 Years
10 Years
25 Years
Max

Payout ratio

Details

Price targets and forecasts for Pfizer are not yet available.

Pfizer Earnings Calls

2025

Nov 4Q3 2025 Earnings Call Transcript

PDF Audio

Aug 5Q2 2025 Earnings Call Transcript

PDF Audio

Apr 29Q1 2025 Earnings Call Transcript

Audio

Feb 4Q4 2024 Earnings Call Transcript

Audio

2024

Oct 29Q3 2024 Earnings Call Transcript

PDF Audio

Jul 30Q2 2024 Earnings Call Transcript

PDF Audio

May 1Q1 2024 Earnings Call Transcript

Audio

Jan 30Q4 2023 Earnings Call Transcript

Audio

2023

Oct 31Q3 2023 Earnings Call Transcript

PDF Audio

Pfizer Earnings Estimates

Date	EPS estimate	Revenue Estimate	Quarterly report
5/5/2026	0.71USD	13.94 BUSD	2026 Q1
2/3/2026	0.58USD	17.13 BUSD	2025 Q4
4/30/2024	0.86USD	15.6 BUSD	2024 Q1
1/29/2024	-0.17USD	14.55 BUSD	2023 Q4
7/26/2023	1.03USD	17.08 BUSD	2023 Q2
5/1/2023	1.25USD	18.85 BUSD	2023 Q1
2/6/2023	1.04USD	24.79 BUSD	2022 Q4
11/1/2022	1.4USD	21.36 BUSD	2022 Q3
7/28/2022	1.8USD	26.12 BUSD	2022 Q2
5/3/2022	1.49USD	24.22 BUSD	2022 Q1
2/8/2022	0.87USD	24.48 BUSD	2021 Q4
11/2/2021	1.1USD	23.05 BUSD	2021 Q3
7/28/2021	0.98USD	19.02 BUSD	2021 Q2
5/4/2021	0.78USD	13.71 BUSD	2021 Q1
2/2/2021	0.49USD	11.6 BUSD	2020 Q4
10/27/2020	0.72USD	12.5 BUSD	2020 Q3
7/28/2020	0.67USD	11.73 BUSD	2020 Q2
4/28/2020	0.74USD	12.05 BUSD	2020 Q1
1/28/2020	0.58USD	12.77 BUSD	2019 Q4
10/29/2019	0.62USD	12.44 BUSD	2019 Q3
7/29/2019	0.76USD	13.6 BUSD	2019 Q2
4/30/2019	0.76USD	13.19 BUSD	2019 Q1
1/29/2019	0.64USD	14.11 BUSD	2018 Q4
10/30/2018	0.75USD	13.74 BUSD	2018 Q3
7/31/2018	0.75USD	13.51 BUSD	2018 Q2
5/1/2018	0.75USD	13.33 BUSD	2018 Q1
1/30/2018	0.57USD	13.89 BUSD	2017 Q4
10/31/2017	0.65USD	13.37 BUSD	2017 Q3
8/1/2017	0.66USD	13.28 BUSD	2017 Q2
5/2/2017	0.68USD	13.29 BUSD	2017 Q1
1/31/2017	0.51USD	13.83 BUSD	2016 Q4
11/1/2016	0.62USD	13.24 BUSD	2016 Q3
8/2/2016	0.63USD	13.21 BUSD	2016 Q2
5/3/2016	0.56USD	12.2 BUSD	2016 Q1
2/2/2016	0.53USD	13.76 BUSD	2015 Q4
10/27/2015	0.51USD	11.73 BUSD	2015 Q3
7/28/2015	0.52USD	11.58 BUSD	2015 Q2
4/28/2015	0.5USD	10.92 BUSD	2015 Q1
1/27/2015	0.53USD	13.09 BUSD	2014 Q4
10/28/2014	0.56USD	12.42 BUSD	2014 Q3
7/29/2014	0.57USD	12.65 BUSD	2014 Q2
5/5/2014	0.56USD	12.26 BUSD	2014 Q1
1/28/2014	0.53USD	13.55 BUSD	2013 Q4
10/29/2013	0.56USD	12.89 BUSD	2013 Q3
7/30/2013	0.56USD	13.21 BUSD	2013 Q2
4/30/2013	0.56USD	14.2 BUSD	2013 Q1
1/29/2013	0.45USD	14.59 BUSD	2012 Q4
11/1/2012	0.53USD	14.86 BUSD	2012 Q3
7/31/2012	0.55USD	15.09 BUSD	2012 Q2
5/1/2012	0.57USD	15.7 BUSD	2012 Q1
1/31/2012	0.47USD	16.86 BUSD	2011 Q4
11/1/2011	0.56USD	16.67 BUSD	2011 Q3
8/2/2011	0.59USD	17.23 BUSD	2011 Q2
5/3/2011	0.59USD	16.87 BUSD	2011 Q1
2/1/2011	0.46USD	17.22 BUSD	2010 Q4
11/2/2010	0.52USD	16.93 BUSD	2010 Q3
8/3/2010	0.53USD	16.9 BUSD	2010 Q2
5/4/2010	0.54USD	16.83 BUSD	2010 Q1
2/3/2010	0.51USD	16.11 BUSD	2009 Q4
10/20/2009	0.49USD	11.58 BUSD	2009 Q3
7/22/2009	0.47USD	11.44 BUSD	2009 Q2
4/28/2009	0.49USD	11.24 BUSD	2009 Q1
1/26/2009	0.6USD	12.72 BUSD	2008 Q4
10/21/2008	0.61USD	12.19 BUSD	2008 Q3
7/23/2008	0.55USD	11.64 BUSD	2008 Q2
4/17/2008	0.67USD	12.29 BUSD	2008 Q1
1/23/2008	0.47USD	12.38 BUSD	2007 Q4
10/18/2007	0.53USD	11.96 BUSD	2007 Q3
7/18/2007	0.5USD	11.57 BUSD	2007 Q2
4/20/2007	0.58USD	11.94 BUSD	2007 Q1
1/22/2007	0.43USD	12.45 BUSD	2006 Q4
10/19/2006	0.46USD	11.58 BUSD	2006 Q3
7/20/2006	0.48USD	12.88 BUSD	2006 Q2
4/19/2006	0.53USD	13.2 BUSD	2006 Q1
1/19/2006	0.43USD	13.36 BUSD	2005 Q4
10/20/2005	0.48USD	12.71 BUSD	2005 Q3
7/20/2005	0.45USD	12.34 BUSD	2005 Q2
4/19/2005	0.53USD	12.71 BUSD	2005 Q1
1/19/2005	0.6USD	14.26 BUSD	2004 Q4
10/20/2004	0.55USD	13.43 BUSD	2004 Q3
7/21/2004	0.47USD	12.53 BUSD	2004 Q2
4/20/2004	0.51USD	12.87 BUSD	2004 Q1
1/22/2004	0.52USD	13.86 BUSD	2003 Q4
10/22/2003	0.44USD	12.36 BUSD	2003 Q3
7/25/2003	0.29USD	11.01 BUSD	2003 Q2
4/22/2003	0.44USD	8.64 BUSD	2003 Q1
1/22/2003	0.48USD	9.99 BUSD	2002 Q4
10/16/2002	0.39USD	8.86 BUSD	2002 Q3
7/15/2002	0.33USD	8.37 BUSD	2002 Q2
4/17/2002	0.4USD	8.95 BUSD	2002 Q1

...

EESG©

73/100

Environment

Social

Governance

Environment

Scope 1 - Direct Emissions620,124

Scope 2 - Indirect emissions from purchased energy500,077

Scope 3 - Indirect emissions within the value chain4,338,487

Total CO₂ emissions1,120,201

CO₂ reduction strategy

Coal energy

Nuclear power

Animal experiments

Fur & Leather—

Pesticides—

Palm Oil—

Tobacco

Genetically modified organisms

Climate concept—

Sustainable forestry—

Recycling regulations

Environmentally friendly packaging

Hazardous substances

Fuel consumption and efficiency

Water consumption and efficiency

Social

Percentage of female employees50.2

Percentage of women in management—

Percentage of Asian employees9

Share of Asian management20.3

Percentage of Hispanic/Latino employees8.4

Hispano/Latino Management share6.9

Percentage of Black employees22.3

Black Management Share6.9

Percentage of white employees56.3

White Management Share63.4

Adult content

Alcohol

Weapons—

Firearms

Gambling

Military contracts

Human rights concept

Privacy concept—

Occupational health and safety

Catholic

Governance (Corporate Governance)

Environmental reporting

Stakeholder Engagement

Call Back Policies

Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Pfizer shareholder structure

%	Name	Stocks	Change	Date
9.28895%	The Vanguard Group, Inc.	530,677,607	+10,095,939	6/30/2025
5.18644%	State Street Investment Management (US)	296,301,310	-669,218	6/30/2025
5.05678%	BlackRock Institutional Trust Company, N.A.	288,893,767	-2,654,127	6/30/2025
2.23125%	Geode Capital Management, L.L.C.	127,471,481	+1,820,634	6/30/2025
1.6393%	Norges Bank Investment Management (NBIM)	93,653,338	+5,866,456	6/30/2025
1.34787%	Wellington Management Company, LLP	77,003,539	-26,490,160	6/30/2025
1.00802%	State Farm Insurance Companies	57,588,032	-158,700	6/30/2025
0.96202%	MFS Investment Management	54,960,108	-17,795,251	9/30/2025
0.95666%	BlackRock Asset Management Ireland Limited	54,653,835	+4,181,775	6/30/2025
0.86058%	Charles Schwab Investment Management, Inc.	49,165,032	+1,135,457	6/30/2025

...

Pfizer Executives and Management Board

Dr. Albert Bourla

(63)

Chairman of the Board, Chief Executive Officer · since 2014

Compensation24.65 MUSD

Compensation24.65 M USD

Mr. Aamir Malik

(49)

Executive Vice President, Chief US Commercial Officer

8.29 MUSD

Compensation8.29 M USD

Mr. David Denton

(59)

Executive Vice President, Chief Financial Officer

8.12 MUSD

Compensation8.12 M USD

Dr. Chris Boshoff

(61)

Chief Scientific Officer, President - Research & Development

7.85 MUSD

Compensation7.85 M USD

Mr. Douglas Lankler

(59)

Executive Vice President, Chief Legal Officer

5.48 MUSD

Compensation5.48 M USD

Pfizer Supply Chain

Frequently asked questions about Pfizer

Pfizer Inc's business model is focused on pharmaceutical research, development, manufacturing, and sales. The company operates in various therapeutic areas, including but not limited to oncology, cardiovascular, immunology, and neurology. Pfizer's mission is to discover and develop innovative medicines that enhance the health and well-being of people worldwide. With a diverse portfolio of prescription medicines, vaccines, and consumer healthcare products, Pfizer strives to improve patient outcomes and provide effective healthcare solutions. Through strategic partnerships and collaborations, Pfizer continues to invest in research and development to address unmet medical needs and drive sustainable growth in the pharmaceutical industry.

Fair Value PRO

27.37 USD

Over-/Undervaluation PRO

30.0% undervalued

Expected Return

1.37 %

Sector

Health

Industry

Pharmaceuticals

Number of shares

5,713,000,000

Employees

78,500

Revenue per Employee

797,184.71 USD

Revenue growth Ø5 years

-5.1 %

EBIT growth Ø5 years

-6.29 %

Net Income growth Ø5 years

-18.77 %

Website pfizer.com

Country

United States 🇺🇸

Currency

USD

Initial public offering

Jan 17, 1944

ISIN

US7170811035

Cusip

717081103

Sedol

2684703

Market capitalization

156.81 B USDLarge Cap

Pfizer Directors Dealings

Quality Investing

3 / 10

Revenue growth (10Y) > 5%

Revenue growth (3Y) > 5 %

EBIT growth (10Y) > 5%

EBIT growth (3Y) > 5 %

Net debt < 4x EBIT

Profitable since 10Y+

EBIT Drawdown (10Y) < 50%

Return on Equity (ROE) > 15%

ROCE > 15%

Return Expectation > 10%

PEG

-5.09

P/E ratio

19.35

P/Ee 2026

8.76

P/Ee 2027

9.13

P/Ee 2028

9.65

P/Ee 2029

12.14

P/Ee 2030

11.86

P/S

2.4

P/Se

2.44

EV/EBIT

7.88

P/B Ratio

1.78

ROE (Return on Equity)

9.11 %

ROA (Return on Assets)

3.76 %

ROCE (Return on Capital Employed)

18.97 %

ROIC (Return on Invested Capital)

5.26 %

Gross Margin

75.81 %

EBIT Margin

31.79 %

Net Margin

12.42 %

EPS (Earnings Per Share)

1.36 USD

Net Debt / EBIT

—

Debt/Equity

0.73

Dividend

1.72 USD

Dividend yield

6.53 %

Est. Dividend Yield

1.63 %

Payout Ratio

41.74 %

Dividend growth Ø5Y

1.97 %

Dividend payments per year

Dividend paid since

36 years

Dividend not reduced since

1 year

Dividend increased since

1 year

Dividend withholding tax

30 %

Last updated Jun 12, 2026, 4:28 AM

Pfizer Presentations

Pfizer Peer Group

Merck & Co Inc

Zoetis Inc

Bristol-Myers Squibb Co

Eli Lilly and Co

Royalty Pharma PLC

Johnson & Johnson

Pfizer Ticker

BERLIN · PFE.BEDÜSSELDORF · PFE.DUFRANKFURT · PFE.FHAMBURG · PFE.HMLONDON · 0Q1N.LMILAN · 1PFE.MIMUNICH · PFE.MUNASDAQ · PFENEW YORK · PFESIX · PFE.SWSTUTTGART · PFE.SGVIENNA · PFE.VI

Pfizer FIGI

PFE:US · BBG000BR2B91PFE:UA · BBG000BR2BK8PFE:UC · BBG000BR2C44PFE:UN · BBG000BR2F10PFE:UP · BBG000BR2FK9PFE:UB · BBG000BR2G81PFE:UT · BBG000BR2GW4PFE:UM · BBG000BR2HX1PFE:UX · BBG000BR2JG6PFE:UD · BBG000BR2ML3PFE:UF · BBG000BR2PZ1PFE:VY · BBG000BR2Q89

All fundamentals and in-depth analysis of Pfizer

Our stock analysis for Pfizer Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pfizer Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Pfizer Directors Dealings→

Pfizer Stocks→

Pfizer Market capitalization→

Pfizer Debt→

Pfizer Liabilities→

Pfizer Equity→